Compare CHCT & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | OCGN |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.6M | 387.3M |
| IPO Year | 2015 | N/A |
| Metric | CHCT | OCGN |
|---|---|---|
| Price | $18.05 | $1.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.50 | $7.00 |
| AVG Volume (30 Days) | 169.3K | ★ 6.2M |
| Earning Date | 02-17-2026 | 03-04-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,547,000.00 | $5,370,000.00 |
| Revenue This Year | $7.32 | $35.88 |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.40 | ★ 14.26 |
| 52 Week Low | $13.23 | $0.52 |
| 52 Week High | $20.28 | $1.96 |
| Indicator | CHCT | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 77.17 | 41.83 |
| Support Level | $16.62 | $1.31 |
| Resistance Level | $18.19 | $1.70 |
| Average True Range (ATR) | 0.35 | 0.09 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 96.83 | 10.98 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").